Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Overhead view of colourful numbers on white background.

 

Professor John Matthews gave an interesting talk about the bias introduced to binary outcomes in randomised controlled trials due to omitted covariates (both known and unknown). The rest of the meeting was taken up with updates and discussion. The Development of Statistical Analysis Plans has been funded by a Methodological grant and will be taken forward over the next few months with the aim of providing guidelines for SAPs, similar to the SPIRIT guidelines for protocols. A project on Trial Steering Committees has also been funded and an update on the Review of current practices and Opinions of Trial Steering Committees and a Review of a cohort of published literature for reporting of the remits and Functions of TSCs was provided. The aim of this project is to provide guidelines and a charter as per the Damocles Charter for Data Monitoring Committees. A discussion around providing a database of expert statisticians who will be able to be approached to be independent statisticians on either a DMC or a TSC was also discussed with particular emphasis on the definition of expert and what searchable features would be required. We also discussed how to enable the development of new statisticians to become experts in order to widen the existing limited pool of experienced experts. 

Similar stories

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.